NASDAQ:VCYT - Veracyte Stock Price, Forecast & News

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte Inc (NASDAQ:VCYT) posted its quarterly earnings data on Tuesday, February, 25th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.07. The biotechnology company had revenue of $29.73 million for the quarter, compared to analysts' expectations of $29.35 million. Veracyte had a negative net margin of 7.08% and a negative return on equity of 5.33%. View Veracyte's Earnings History.

Veracyte updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138-142 million, compared to the consensus revenue estimate of $136.41 million.

2 analysts have issued 1-year target prices for Veracyte's stock. Their forecasts range from $30.00 to $35.00. On average, they anticipate Veracyte's stock price to reach $32.50 in the next year. This suggests a possible upside of 41.4% from the stock's current price. View Analyst Price Targets for Veracyte.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.

Headlines about VCYT stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Veracyte earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the next several days. View News Stories for Veracyte.

Veracyte saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 3,610,000 shares, an increase of 42.7% from the January 15th total of 2,530,000 shares. Based on an average daily trading volume, of 498,600 shares, the short-interest ratio is presently 7.2 days. Currently, 7.7% of the shares of the stock are short sold. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD) and Miragen Therapeutics (MGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), AbbVie (ABBV), BlackRock (BLK), Advanced Micro Devices (AMD), InVitae (NVTA), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Geron (GERN).

Veracyte's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (7.31%), Sumitomo Mitsui Trust Holdings Inc. (6.25%), Nikko Asset Management Americas Inc. (6.25%), ARK Investment Management LLC (5.71%), State Street Corp (4.08%) and Artisan Partners Limited Partnership (3.76%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Institutional Ownership Trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Robeco Institutional Asset Management B.V., Bamco Inc. NY, AQR Capital Management LLC, State Street Corp, Calamos Advisors LLC, Essex Investment Management Co. LLC and UBS Group AG. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Insider Buying and Selling for Veracyte.

VCYT stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, GW&K Investment Management LLC, William Blair Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Lord Abbett & CO. LLC, New York State Common Retirement Fund and Pictet Asset Management Ltd.. View Insider Buying and Selling for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $22.99.

Veracyte has a market capitalization of $1.12 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.

The official website for Veracyte is http://www.veracyte.com/.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]